Broncho-alveolar inflammation in COVID-19 patients: a correlation with clinical outcome.
Adenosine Monophosphate
/ analogs & derivatives
Adrenal Cortex Hormones
/ therapeutic use
Aged
Alanine
/ analogs & derivatives
Antibodies, Monoclonal, Humanized
/ therapeutic use
Antiviral Agents
/ therapeutic use
Betacoronavirus
Bronchoalveolar Lavage
Bronchoalveolar Lavage Fluid
/ cytology
COVID-19
Coronavirus Infections
/ drug therapy
Drug Combinations
Female
Humans
Hydroxychloroquine
/ therapeutic use
Inflammation
/ immunology
Intensive Care Units
Interleukin-10
/ immunology
Interleukin-6
/ immunology
Interleukin-8
/ immunology
Italy
Leukocytes
/ immunology
Leukocytes, Mononuclear
/ virology
Lopinavir
/ therapeutic use
Lung
/ cytology
Lymphocytes
/ immunology
Macrophages, Alveolar
/ immunology
Male
Microscopy, Electron, Transmission
Middle Aged
Neutrophils
/ immunology
Pandemics
Pneumonia, Viral
/ immunology
Prognosis
Prospective Studies
Respiration, Artificial
/ methods
Ritonavir
/ therapeutic use
SARS-CoV-2
Spike Glycoprotein, Coronavirus
/ metabolism
Survival Rate
Virion
/ metabolism
COVID-19 Drug Treatment
Bronchoalveolar lavage
COVID-19
Cytokines
Lung
SARS-CoV-2
Journal
BMC pulmonary medicine
ISSN: 1471-2466
Titre abrégé: BMC Pulm Med
Pays: England
ID NLM: 100968563
Informations de publication
Date de publication:
16 Nov 2020
16 Nov 2020
Historique:
received:
28
07
2020
accepted:
09
11
2020
entrez:
17
11
2020
pubmed:
18
11
2020
medline:
20
11
2020
Statut:
epublish
Résumé
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) rapidly reached pandemic proportions. Given that the main target of SARS-CoV-2 are lungs leading to severe pneumonia with hyperactivation of the inflammatory cascade, we conducted a prospective study to assess alveolar inflammatory status in patients with moderate to severe COVID-19. Diagnostic bronchoalveolar lavage (BAL) was performed in 33 adult patients with SARS-CoV-2 infection by real-time PCR on nasopharyngeal swab admitted to the Intensive care unit (ICU) (n = 28) and to the Intermediate Medicine Ward (IMW) (n = 5). We analyze the differential cell count, ultrastructure of cells and Interleukin (IL)6, 8 and 10 levels. ICU patients showed a marked increase in neutrophils (1.24 × 10 Alveolitis, associated with COVID-19, is mainly sustained by innate effectors which showed features of extensive activation. The burden of pro-inflammatory cytokines IL6 and IL8 in the broncho-alveolar environment is associated with clinical outcome.
Sections du résumé
BACKGROUND
BACKGROUND
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) rapidly reached pandemic proportions. Given that the main target of SARS-CoV-2 are lungs leading to severe pneumonia with hyperactivation of the inflammatory cascade, we conducted a prospective study to assess alveolar inflammatory status in patients with moderate to severe COVID-19.
METHODS
METHODS
Diagnostic bronchoalveolar lavage (BAL) was performed in 33 adult patients with SARS-CoV-2 infection by real-time PCR on nasopharyngeal swab admitted to the Intensive care unit (ICU) (n = 28) and to the Intermediate Medicine Ward (IMW) (n = 5). We analyze the differential cell count, ultrastructure of cells and Interleukin (IL)6, 8 and 10 levels.
RESULTS
RESULTS
ICU patients showed a marked increase in neutrophils (1.24 × 10
CONCLUSIONS
CONCLUSIONS
Alveolitis, associated with COVID-19, is mainly sustained by innate effectors which showed features of extensive activation. The burden of pro-inflammatory cytokines IL6 and IL8 in the broncho-alveolar environment is associated with clinical outcome.
Identifiants
pubmed: 33198751
doi: 10.1186/s12890-020-01343-z
pii: 10.1186/s12890-020-01343-z
pmc: PMC7668012
doi:
Substances chimiques
Adrenal Cortex Hormones
0
Antibodies, Monoclonal, Humanized
0
Antiviral Agents
0
Drug Combinations
0
Interleukin-6
0
Interleukin-8
0
Spike Glycoprotein, Coronavirus
0
lopinavir-ritonavir drug combination
0
spike protein, SARS-CoV-2
0
Interleukin-10
130068-27-8
Lopinavir
2494G1JF75
remdesivir
3QKI37EEHE
Adenosine Monophosphate
415SHH325A
Hydroxychloroquine
4QWG6N8QKH
tocilizumab
I031V2H011
Ritonavir
O3J8G9O825
Alanine
OF5P57N2ZX
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
301Références
Blood. 2020 Sep 3;136(10):1169-1179
pubmed: 32597954
Br J Haematol. 2020 May;189(3):428-437
pubmed: 32297671
J Immunol. 2008 May 1;180(9):5771-7
pubmed: 18424693
Intensive Care Med. 2020 May;46(5):846-848
pubmed: 32125452
Lancet. 2020 Jun 6;395(10239):1771-1778
pubmed: 32410760
Eur Respir J. 2020 Oct 15;56(4):
pubmed: 32859682
Am J Respir Crit Care Med. 2020 Sep 15;202(6):812-821
pubmed: 32584597
J Exp Med. 2020 Jun 1;217(6):
pubmed: 32302401
Nature. 2020 Mar;579(7798):265-269
pubmed: 32015508
N Engl J Med. 2000 May 4;342(18):1301-8
pubmed: 10793162
Clin Exp Rheumatol. 2009 Sep-Oct;27(5):765-72
pubmed: 19917158
Nat Med. 2020 Jun;26(6):842-844
pubmed: 32398875
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Emerg Microbes Infect. 2020 Dec;9(1):1123-1130
pubmed: 32475230
Cytokine. 2020 Feb;126:154895
pubmed: 31706200
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Autoimmun Rev. 2020 Jun;19(6):102537
pubmed: 32251717